Considerations in the statistical analysis of hemodialysis patient survival

Journal of the American Society of Nephrology

Volumn 20, Issue 9, 2009, Pages 2034-2043

  Argyropoulos, Christos ^a   Chang, Chung Chou H ^b,c   Plantinga, Laura ^e   Fink, Nancy ^d,e   Powe, Neil ^d,e   Unruh, Mark ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; DEMOGRAPHY; FEMALE; FOLLOW UP; GROUPS BY AGE; HAZARD RATIO; HEART FAILURE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; SURVIVAL RATE;

ADULT; AGED; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; REGRESSION ANALYSIS; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 69849092174     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008050551     Document Type: Article

References (76)

1. Lowrie EG, Laird NM, Parker TF, Sargent JA: Effect of the hemodialysis prescription of patient morbidity: Report from the National Cooperative Dialysis Study. N Engl J Med 305: 1176-1181, 1981
2. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, Mujais S: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13: 1307-1320, 2002 (Pubitemid 34441412)
3. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010-2019, 2002 (Pubitemid 35461657)
4. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329: 1001-1006, 1993 (Pubitemid 23307908)
5. Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J, Akiba T, Mapes DL, Young EW, Port FK: Longer treatment time and slower ultrafiltration in hemodialysis: Associations with reduced mortality in the DOPPS. Kidney Int 69: 1222-1228, 2006
6. Shinzato T, Nakai S, Akiba T, Yamazaki C, Sasaki R, Kitaoka T, Kubo K, Shinoda T, Kurokawa K, Marumo F, Sato T, Maeda K: Survival in long-term haemodialysis patients: results from the annual survey of the Japanese Society for Dialysis Therapy. Nephrol Dial Transplant 11: 2139-2142, 1996 (Pubitemid 26385905)
7. Lo WK, Ho YW, Li CS, Wong KS, Chan TM, Yu AW, Ng FS, Cheng IK: Effect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study. Kidney Int 64: 649-656, 2003
8. Vanholder R, De Smet R, Jacobs V, Van Landschoot N, Waterloos MA, Vogeleere P, Ringoir S: Uraemic toxic retention solutes depress polymorphonuclear response to phagocytosis. Nephrol Dial Transplant 9: 1271-1278, 1994 (Pubitemid 24283653)
9. Vanholder R, De Smet R, Vogeleere P, Ringoir S: Middle molecules: Toxicity and removal by hemodialysis and related strategies. Artif Organs 19: 1120-1125, 1995
10. Vanholder R, De Smet R: Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 10: 1815-1823, 1999
11. Bagdonavicius VB: A Statistical Test of a Model of Additive Accumulation of Damage. Theory of Probability and its Applications 23: 385-390, 1979
12. Reid N: A conversation with Sir David Cox. Stat Sci 9: 439-455, 1994
13. Cox DR: Regression models, life-tables. With discussion by F. Downton, Richard Peto, D.J. Bartholomew, D.V. Lindley, P.W. Glassborow, D.E. Barton, Susannah Howard, B. Benjamin, John J. Gart, L.D. Meshalkin, A.R. Kagan, M. Zelen, R.E. Barlow, Jack Kalbfleisch, R.L. Prentice and Norman Breslow, and a reply by D.R. Cox. J R Stat Soc Ser B 34: 187-220, 1972
14. Wenqing H, Jerald FL: Bivariate location-scale models for regression analysis, with applications to lifetime data. J R Stat Soc B 67: 63-78, 2005 (Pubitemid 40167041)
15. Keiding N, Andersen PK, Klein JP: The role of frailty models and accelerated failure time models in describing heterogeneity due to omitted covariates. Stat Med 16: 215-224, 1997 (Pubitemid 27029298)
16. Heagerty PJ, Zheng Y: Survival model predictive accuracy and ROC curves. Biometrics 61: 92-105, 2005
17. Hutton JL, Monaghan PF: Choice of parametric accelerated life and proportional hazards models for survival data: asymptotic results. Lifetime Data Anal 8: 375-393, 2002
18. Chapman JA, Trudeau ME, Pritchard KI, Sawka CA, Mobbs BG, Hanna WM, Kahn H, McCready DR, Lickley LA: A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer. Breast Cancer Res Treat 22: 263-272, 1992
19. Chapman JA, Lickley HL, Trudeau ME, Hanna WM, Kahn HJ, Murray D, Sawka CA, Mobbs BG, McCready DR, Pritchard KI: Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis. Breast J 12: 37-47, 2006 (Pubitemid 43381448)
20. Cole SR, Hernan MA, Robins JM, Anastos K, Chmiel J, Detels R, Ervin C, Feldman J, Greenblatt R, Kingsley L, Lai S, Young M, Cohen M, Munoz A: Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol 158: 687-694, 2003 (Pubitemid 37175517)
21. Lin DY, Fischl MA, Schoenfeld DA: Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med 12: 835-842, 1993
22. Heller G, Simonoff JS: Prediction in censored survival data: A comparison of the proportional hazards and linear regression models. Biometrics 48: 101-115, 1992
23. Lawless JF: Inference for log-location-scale (accelerated failure time) models. In: Statistical Models and Methods for Lifetime Data, 2nd Ed., Hoboken, NJ, Wiley Interscience, 2002, pp 292-311
24. Gotch F: Kinetic modeling in hemodialysis. In: Clinical Dialysis, 4th Ed., edited by Nissenson AR, Fine RN, McGraw Hill-Professional, 2005, pp 153-202
25. Sackett DL: Why randomized controlled trials fail but needn't: 2. Failure to employ physiological statistics, or the only formula a clinician-trialist is ever likely to need (or understand!). CMAJ 165: 1226-1237, 2001
26. Solomon PJ: Effect of misspecification of regression models in the analysis of survival data. Biometrika 71: 291-298, 1984
27. Chertow GM, Owen WF, Lazarus JM: Outcomes of older patients receiving chronic dialysis. JAMA 272: 274, 1994
28. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergstrom J: Factors predicting malnutrition in hemodialysis patients: A cross-sectional study. Kidney Int 53: 773-782, 1998 (Pubitemid 28124295)
29. Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimburger O, Lindholm B, Bergstrom J: Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13[Suppl 1]: S28-S36, 2002
30. Johansen KL, Chertow GM, Ng AV, Mulligan K, Carey S, Schoenfeld PY, Kent-Braun JA: Physical activity levels in patients on hemodialysis and healthy sedentary controls. Kidney Int 57: 2564-2570, 2000 (Pubitemid 30340755)
31. Dwyer JT, Larive B, Leung J, Rocco MV, Greene T, Burrowes J, Chertow GM, Cockram DB, Chumlea WC, Daugirdas J, Frydrych A, Kusek JW: Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? Kidney Int 68: 1766-1776, 2005 (Pubitemid 43169921)
32. Lowrie E, LePain L, Zhang H, Lew N, Lazarus J: Preliminary Evaluation of the SF-36 among Hemodialysis Patients, Lexington, MA, Fresenius Medical Care, 1997
33. Lowrie EG, Curtin RB, Lepain N, Schatell D: Medical outcomes study short form-36: A consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis 41: 1286-1292, 2003
34. Iest CG, Vanholder RC, Ringoir SM: Loss of residual renal function in patients on regular haemodialysis. Int J Artif Organs 12: 159-164, 1989
35. Aalen OO, Gjessing HK: Understanding the shape of the hazard rate: A process point of view (with comments and a rejoinder by the authors). Stat Sci 16: 1-22, 2001
36. De Smet R, Van Kaer J, Van Vlem B, De Cubber A, Brunet P, Lameire N, Vanholder R: Toxicity of free p-cresol: A prospective and cross-sectional analysis. Clin Chem 49: 470-478, 2003 (Pubitemid 36250208)
37. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P: The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 65: 442-451, 2004 (Pubitemid 38130638)
38. Ferreira A, Urena P, Ang KS, Simon P, Morieux C, Souberbielle JC, de Vernejoul MC, Drueke TB: Relationship between serum beta 2-microglobulin, bone histology, and dialysis membranes in uraemic patients. Nephrol Dial Transplant 10: 1701-1707, 1995
39. Stiller S, Xu XQ, Gruner N, Vienken J, Mann H: Validation of a two-pool model for the kinetics of beta2-microglobulin. Int J Artif Organs 25: 411-420, 2002
40. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, Agodoa L, Bailey J, Beck GJ, Clark W, Levey AS, Ornt DB, Schulman G, Schwab S, Teehan B, Eknoyan G: Serum beta-2 microglobulin levels predict mortality in dialysis patients: Results of the HEMO study. J Am Soc Nephrol 17: 546-555, 2006
41. Eloot S, Torremans A, De Smet R, Marescau B, De Deyn PP, Verdonck P, Vanholder R: Complex compartmental behavior of small water-soluble uremic retention solutes: Evaluation by direct measurements in plasma and erythrocytes. Am J Kidney Dis 50: 279-288, 2007 (Pubitemid 47095079)
42. Meert N, Schepers E, De Smet R, Argiles A, Cohen G, Deppisch R, Drueke T, Massy Z, Spasovski G, Stegmayr B, Zidek W, Jankowski J, Vanholder R: Inconsistency of reported uremic toxin concentrations. Artif Organs 31: 600-611, 2007 (Pubitemid 47101111)
43. Cohen G, Glorieux G, Thornalley P, Schepers E, Meert N, Jankowski J, Jankowski V, Argiles A, Anderstam B, Brunet P, Cerini C, Dou L, Deppisch R, Marescau B, Massy Z, Perna A, Raupachova J, Rodriguez M, Stegmayr B, Vanholder R, Horl WH: Review on uraemic toxins III: Recommendations for handling uraemic retention solutes in vitro towards a standardized approach for research on uraemia. Nephrol Dial Transplant 22: 3381-3390, 2007 (Pubitemid 350212473)
44. Eloot S, Torremans A, De Smet R, Marescau B, De Wachter D, De Deyn PP, Lameire N, Verdonck P, Vanholder R: Kinetic behavior of urea is different from that of other water-soluble compounds: The case of the guanidino compounds. Kidney Int 67: 1566-1575, 2005 (Pubitemid 40463137)
45. Glorieux GL, Dhondt AW, Jacobs P, Van Langeraert J, Lameire NH, De Deyn PP, Vanholder RC: In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 65: 2184-2192, 2004 (Pubitemid 38670004)
46. Weissinger EM, Kaiser T, Meert N, De Smet R, Walden M, Mischak H, Vanholder RC: Proteomics: A novel tool to unravel the patho-physiology of uraemia. Nephrol Dial Transplant 19: 3068-3077, 2004 (Pubitemid 40057630)
47. Drai J, Bannier E, Chazot C, Hurot JM, Goedert G, Jean G, Charra B, Laurent G, Baltassat P, Revol A: Oxidants and antioxidants in longterm haemodialysis patients. Farmaco 56: 463-465, 2001 (Pubitemid 32622119)
48. US Renal Data System: The USRDS Dialysis Morbidity and Mortality Study (Wave 2). Am J Kidney Dis 30[Suppl]: S67-S85, 1997 (Pubitemid 27337986)
49. US Renal Data System: The USRDS Dialysis Morbidity and Mortality Study (Wave I). Am J Kidney Dis 28[Suppl]: S58-S78, 1996
50. Buckley J, James I: Linear regression with censored data. Biometrika 66: 429-436, 1979
51. Jin Z, Lin DY, Ying Z: On least-squares regression with censored data. Biometrika 93:147-161, 2006
52. Huang L, Jin Z: LSS: An S-Plus/R program for the accelerated failure time model to right censored data based on least-squares principle. Comput Methods Programs Biomed 86: 45-50, 2007 (Pubitemid 46366017)
53. Greene T, Daugirdas J, Depner T, Allon M, Beck G, Chumlea C, Delmez J, Gotch F, Kusek JW, Levin N, Owen W, Schulman G, Star R, Toto R, Eknoyan G: Association of achieved dialysis dose with mortality in the hemodialysis study: An example of "dose-targeting bias." J Am Soc Nephrol 16: 3371-3380, 2005
54. Lowrie EG: The kinetic behaviors of urea and other marker molecules during hemodialysis. Am J Kidney Dis 50: 181-183, 2007
55. Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS, Levin NW, Sadler JH, Kliger A, Powe NR: Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 143: 174-183, 2005 (Pubitemid 41076750)
56. Athienites NV, Miskulin DC, Fernandez GF, Bunnapradist S, Simon G, Landa M, Schmid C, Greenfield S, Levey AS, Meyer KB: Comorbidity assessment in hemodialysis and peritoneal dialysis using the Index of Coexistent Disease (ICED). Semin Dial 13: 320-326, 2000
57. Miskulin DC, Athienites NV, Yan G, Martin AA, Ornt DB, Kusek JW, Meyer KB, Levey AS: Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial. Kidney Int 60: 1498-1510, 2001 (Pubitemid 32960045)
58. Allen KL, Miskulin D, Yan G, Dwyer JT, Frydrych A, Leung J, Poole D, Hemodialysis Study Group: Association of nutritional markers with physical and mental health status in prevalent hemodialysis patients from the HEMO study. J Ren Nutr 12: 160-169, 2002
59. Daugirdas JT: Second generation logarithmic estimates of single-pool variable volumeKt/V: An analysis of error. J Am Soc Nephrol 4: 1205-1213, 1993
60. Mesler DE, McCarthy EP, Byrne-Logan S, Ash AS, Moskowitz MA: Does the survival advantage of nonwhite dialysis patients persist after case mix adjustment? Am J Med 106: 300-306, 1999 (Pubitemid 29153407)
61. Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS, Levin NW, Sadler JH, Kliger A, Powe NR: Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 143: 174-183, 2005 (Pubitemid 41076750)
62. Plantinga LC, Fink NE, Levin NW, Jaar BG, Coresh J, Levey AS, Klag MJ, Powe NR: Early, intermediate, and long-term risk factors for mortality in incident dialysis patients: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. Am J Kidney Dis 49: 831-840, 2007 (Pubitemid 46802937)
63. Miskulin DC, Martin AA, Brown R, Fink NE, Coresh J, Powe NR, Zager PG, Meyer KB, Levey AS: Predicting 1 year mortality in an outpatient haemodialysis population: A comparison of comorbidity instruments. Nephrol Dial Transplant 19: 413-420, 2004 (Pubitemid 38195992)
64. Banerjee D, Ma JZ, Collins AJ, Herzog CA: Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure, pulmonary edema, or fluid overload. Clin J Am Soc Nephrol 2: 1186-1190, 2007
65. Unruh M, Hartunian M, Chapman M, Jaber B: Sleep quality and clinical correlates in patients on maintenance hemodialysis. Clin Nephrol 59: 280-288, 2003 (Pubitemid 36503547)
66. Goldwasser P, Mittman N, Antignani A, Burrell D, Michel MA, Collier J, Avram MM: Predictors of mortality in hemodialysis patients. J Am Soc Nephrol 3: 1613-1622, 1993
67. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 7: 728-736, 1996 (Pubitemid 27466006)
68. Ware J, Snow K, Kosinski M, Gandek B: SF-36 Health Survey Manual and Interpretation Guide, Boston, The Health Institute, New England Medical Center, 1993
69. Curtin RB, Lowrie EG, DeOreo PB: Self-reported functional status: An important predictor of health outcomes among end-stage renal disease patients. Adv Ren Replace Ther 6: 141-148, 1999
70. Fleming TR, O'Fallon JR, O'Brien PC, Harrington DP: Modified Kolmogorov-Smirnov test procedures with application to arbitrarily right-censored data. Biometrics 36: 607-625, 1980
71. Harrell FE, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361-387, 1996
72. Therneau T, Grambsh P: Testing proportional hazards. In: Modeling Survival Data: Extending the Cox Model, New York, Springer-Verlag, 2002, pp 127-152
73. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526, 1994
74. R Development Core Team: R: A Language and Environment for Statistical Computing, Vienna, Austria, R Foundation for Statistical Computing, 2007
75. Harrell FE: Design: Design Package. 2.1-1 ed., 2007. Available at http://cran.r-project.org/web/packages/Design/index.html
76. S original by Terry Therneau ported by Thomas Lumley: survival: Survival analysis, including penalised likelihood. 2.32 ed., 2002. Available at http://cran.r-project.org/web/packages/survival/index.html